Greens Crafted For the Down Syndrome Community

For years, families in the Down syndrome community have heard the same advice about brain health:

“Try this one nutrient.”
“Add this one antioxidant.”
“Here’s the magic ingredient.”

But the science tells a different story and we have formulated a new greens blend for adults and kids in an effort to support the unique health needs associated with Down syndrome*.

Cognitive decline and Alzheimer’s disease are not single-pathway problems. They are systems-level processes that begin decades before symptoms ever appear. When you understand the biology behind chromosome 21, oxidative stress, methylation vulnerability, inflammation, mitochondrial strain, and early Alzheimer’s neuropathology, one thing becomes clear:

Nutrition has to reflect that complexity.

This is not about promising outcomes.
It’s about explaining why these ingredients were chosen.

Alzheimer’s Is a Systems Condition

Modern research shows Alzheimer’s involves an interaction between:

• Oxidative stress

• Neuroinflammation

• Mitochondrial dysfunction

• Amyloid and tau pathology

• Neurotransmitter depletion

• Metabolic and vascular dysfunction

This is why single-target approaches consistently fall short. Layered, complementary mechanisms are required to create resilience. That philosophy is the foundation of this formula.

Why This Approach Is Especially Relevant in Down Syndrome

Down syndrome changes the equation.

Triplication of chromosome 21 leads to ~50% overexpression of the SOD1 gene, creating excessive hydrogen peroxide and reactive oxygen species. Oxidative stress begins prenatally and accelerates across the lifespan. Nearly all individuals with Down syndrome develop Alzheimer’s neuropathology by age 40 (often decades before symptoms).

This is lifelong biology, not a late-life issue.

Oxidative & Redox Defense

Because SOD1 overexpression creates imbalance in peroxide clearance, single antioxidants are rarely sufficient. This is where Vitamin E, selenium, NAC, and curcumin work together to support glutathione systems, mitochondrial protection, and redox balance.

Human trials haven’t always shown cognitive change, but many were not powered to detect it. Lack of benefit does not mean lack of biological relevance.

Methylation, Metabolism & Brain Energy

Elevated homocysteine and metabolic stress are well documented in Down syndrome. Methylcobalamin, 5-MTHF, magnesium, and choline support:

• Methylation pathways

• Neurotransmitter synthesis

• Glucose metabolism

• Brain energy production

Homocysteine reduction remains one of the few modifiable risk factors identified in DS research.

Neuroinflammation, Membranes & Signaling

Chronic inflammatory signaling begins early in DS. Omega-3 fatty acids, zinc, and vitamin D3 support:

• Anti-inflammatory lipid mediators

• Neuronal membrane integrity

• Immune and neurochemical balance

Zinc is included thoughtfully for antioxidant enzymes, neurotransmission, and thyroid support (without megadosing).

Early Neurodegeneration Support

Processes like amyloid aggregation, tau changes, and nerve degeneration occur earlier and more extensively in DS. Curcumin, Lion’s Mane, and Bacopa monnieri provide adjunctive support for nerve growth factors, memory pathways, and antioxidant protection within a broader system.

Gut–Brain–Metabolic Connection

Because gut health, inflammation, and glucose regulation all influence brain outcomes, prebiotics, cinnamon, and polyphenol antioxidants are included to reinforce this triangle.

Why Timing Matters

Oxidative and metabolic stress begin early... long before symptoms. Alzheimer’s pathology develops decades before dementia. Nutritional strategies should be preventive and foundational, not reactive.

Evidence Reality Check

Meta-analyses across interventions show small-to-moderate effects and high variability. This strongly suggests no single agent is sufficient. Multi-target approaches are likely necessary.

That’s exactly what this ingredient panel reflects: biological plausibility, safety, and breadth—not isolated claims.

A Systems-Based Approach to Brain Support

Rather than asking one ingredient to carry the load, this formula layers:

• Omega-3s for structural brain support

• Methylated B vitamins, magnesium, and choline for metabolic stability

• Selenium, NAC, vitamin E, and curcumin for redox defense

• Zinc and vitamin D for immune and neurochemical balance

• Botanicals for memory, nerve growth, and antioxidant activity

• Prebiotics and polyphenols for gut and glucose support

Overlapping pathways create resilience.

DFG 01 vs DFG Kids: Same Science, Different Needs

Both formulas share the same systems-based philosophy and daily-use practicality. They differ in developmental appropriateness, dosing, and sensory tolerance.

We chose thoughtful restraint over aggressive dosing.

Building Brain Health With Integrity

We don’t believe in exaggeration. We believe families deserve to understand why ingredients are chosen and not just told to take them.

Down For Greens was built as a supportive foundation, not a cure. A way to think in systems, not supplements.

If you’ve ever felt overwhelmed trying to piece together dozens of nutrients from different bottles, this is our attempt to bring that science into one thoughtful daily practice.

Sources: 

• Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016). Dementia in Down’s syndrome. The Lancet Neurology.
• Martini, A. C., Gross, T. J., Head, E., & Mapstone, M. (2022). Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome. Neuron.
• Thiel, R., & Fowkes, S. W. (2004). Can cognitive deterioration associated with Down syndrome be reduced? Medical Hypotheses.
• Rueda Revilla, N., & Martínez-Cué, C. (2020). Antioxidants in Down syndrome: From preclinical studies to clinical trials. Antioxidants.
• de la Torre, R., de Sola, S., Hernandez, G., et al. (2016). Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology.
• Azimzadeh, M., Cheah, P. S., & Ling, K. H. (2024). Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer’s disease and its potential as a therapeutic target. Biochemical and Biophysical Research Communications.
• Castro, P., Zaman, S., & Holland, A. (2017). Alzheimer’s disease in people with Down’s syndrome: The prospects for and the challenges of developing preventative treatments. Journal of Neurology.
• Munn, E. E., Montelongo, A., Patel, V. K., et al. (2025). A meta-analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer’s disease in adults with Down syndrome. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
• de Oliveira, L. C., & de Paula Faria, D. (2022). Pharmacological approaches to the treatment of dementia in Down syndrome: A systematic review of randomized clinical studies. Molecules.
• Wei, B. Z., Li, L., Dong, C. W., Tan, C. C., & Xu, W. (2023). The relationship of omega-3 fatty acids with dementia and cognitive decline: Evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. The American Journal of Clinical Nutrition.
• Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018). Nutrition and prevention of cognitive impairment. The Lancet Neurology.
• Wood, A. H. R., Chappell, H. F., & Zulyniak, M. A. (2022). Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease. European Journal of Nutrition.
• Welty, F. K. (2023). Omega-3 fatty acids and cognitive function. Current Opinion in Lipidology.
• Welty, F. K., Daher, R., & Garelnabi, M. (2023). Fish and omega-3 fatty acids: Sex and racial differences in cardiovascular outcomes and cognitive function. Arteriosclerosis, Thrombosis, and Vascular Biology.
• Saleh, R. N. M., & Minihane, A. M. (2022). Fish, n-3 fatty acids, cognition and dementia risk: Not just a fishy tale. Proceedings of the Nutrition Society.
• Wang, Z., Zhu, W., Xing, Y., Jia, J., & Tang, Y. (2022). B vitamins and prevention of cognitive decline and incident dementia: A systematic review and meta-analysis. Nutrition Reviews.
• Douaud, G., Refsum, H., de Jager, C. A., et al. (2013). Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proceedings of the National Academy of Sciences of the United States of America.
• Kacerova, T., Yates, A. G., Dai, J., et al. (2025). Role of B vitamins in modulating homocysteine and metabolic pathways linked to brain atrophy: Metabolomics insights from the VITACOG trial. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
• Zhang, C., Hu, Y., Cao, X., et al. (2025). Lower water-soluble vitamins and higher homocysteine are associated with neurodegenerative diseases. Scientific Reports.
• Reynolds, E. (2006). Vitamin B12, folic acid, and the nervous system. The Lancet Neurology.
• Pereira, M. E., Souza, J. V., Galiciolli, M. E. A., et al. (2022). Effects of selenium supplementation in patients with mild cognitive impairment or Alzheimer’s disease: A systematic review and meta-analysis. Nutrients.
• Rayman, M. P. (2012). Selenium and human health. The Lancet.
• Van der Jeugd, A., Parra-Damas, A., Baeta-Corral, R., et al. (2018). Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-Ad mice. Scientific Reports.
• Daneshpour, A., Leite, M. E. N., & Wagner, K. H. (2025). Selenium and brain aging: A comprehensive review with a focus on hippocampal neurogenesis. Ageing Research Reviews.
• Bragais, E. K., Luna, K. L. D., & Timoteo-Garcia, V. J. (2025). A narrative review on the neuroprotective effects of selenium and vitamin D in Alzheimer’s disease. Biological Trace Element Research.
• Bayo Jimenez, M. T., Rivas-García, L., & Sánchez-González, C. (2025). Natural products in Alzheimer’s disease: A systematic review of clinical trials and underlying molecular mechanisms. International Journal of Molecular Sciences.
• Voulgaropoulou, S. D., van Amelsvoort, T. A. M. J., Prickaerts, J., & Vingerhoets, C. (2019). The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Research.
• Shabbir, A., Rehman, K., Akbar, M., & Akash, M. S. H. (2022). Neuroprotective potential of curcuminoids in modulating Alzheimer’s disease multiple signaling pathways. Current Medicinal Chemistry.
• Gagliardi, S., Morasso, C., Stivaktakis, P., et al. (2020). Curcumin formulations and trials: What’s new in neurological diseases. Molecules.
• Wiciński, M., Fajkiel-Madajczyk, A., Wójcicki, J., Ozorowski, M., & Szambelan, M. (2025). The role of Bacopa monnieri in Alzheimer’s disease: Mechanisms and potential clinical use—A review. Nutrients.
• Khandia, R., Viswanathan, N., Singhal, S., et al. (2022). Ameliorative effects of phytomedicines on Alzheimer’s patients. Current Alzheimer Research.
• Chakraborty, S., Shankaranarayana Rao, B. S., & Tripathi, S. J. (2025). The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders: From modulation of glutamatergic transmission to restoration of synaptic plasticity. Neuropharmacology.
• Ontawong, A., Nehra, G., Maloney, B. J., et al. (2025). N-acetylcysteine attenuates Aβ-mediated oxidative stress, blood-brain barrier leakage, and renal dysfunction in 5xFAD mice. International Journal of Molecular Sciences.
• Tardiolo, G., Bramanti, P., & Mazzon, E. (2018). Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules.
• Alkandari, A. F., Madhyastha, S., & Rao, M. S. (2023). N-acetylcysteine amide against Aβ-induced Alzheimer’s-like pathology in rats. International Journal of Molecular Sciences.
• Kumar, P., Osahon, O. W., & Sekhar, R. V. (2023). GlyNAC (glycine and N-acetylcysteine) supplementation in old mice improves brain glutathione deficiency and reverses age-associated cognitive decline. Antioxidants.
• McCarty, M. F., DiNicolantonio, J. J., & Lerner, A. (2021). A fundamental role for oxidants and intracellular calcium signals in Alzheimer’s pathogenesis—and how a comprehensive antioxidant strategy may aid prevention. International Journal of Molecular Sciences.
• Abbas, K., Mustafa, M., Alam, M., et al. (2025). Multi-target approach to Alzheimer’s disease prevention and treatment: Antioxidant, anti-inflammatory, and amyloid-modulating mechanisms. Neurogenetics.
• Wang, J., Yu, Z., Peng, Y., & Xu, B. (2023). Insights into prevention mechanisms of bioactive components from healthy diets against Alzheimer’s disease. The Journal of Nutritional Biochemistry.
• Mani, S., Dubey, R., Lai, I. C., et al. (2023). Oxidative stress and natural antioxidants in the neurological mechanisms of Alzheimer’s disease. Journal of Alzheimer’s Disease.
• Mishra, A. K., Srivastava, A., & Raj, V. (2024). Recent updates on Alzheimer’s disease: Pathogenesis, pathophysiology, molecular approaches, and natural bioactive compounds. Current Alzheimer Research.
• McGurran, H., Glenn, J., Madero, E., & Bott, N. (2020). Risk reduction and prevention of Alzheimer’s disease: Biological mechanisms of diet. Current Alzheimer Research.